Physician profile
Margaret Coplin
NPI 1093743551
$1,785.86
in general payments reported to CMS, 2019-2025
29 companies · $14.98 in 2025
The $14.98 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $144 · 2021: $213 · 2022: $113 · 2023: $300 · 2024: $44.01 · 2025: $14.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $289.32 | 2019-2023 | |
| Janssen Biotech, INC. | $184.00 | 2019-2021 | |
| Pfizer INC. | $168.27 | 2019-2021 | |
| Astellas Pharma US INC | $109.65 | 2019 | |
| Merck Sharp & Dohme LLC | $106.83 | 2019-2021 | |
| Lilly USA, LLC | $106.09 | 2019-2023 | |
| Amgen INC. | $79.95 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $68.57 | 2023-2025 | Imfinzi, Tagrisso |
| Pharmacyclics LLC, An Abbvie Company | $63.18 | 2019 | |
| Incyte Corporation | $53.53 | 2019-2022 | |
| Seagen INC. | $42.48 | 2020-2023 | Tukysa |
| Celgene Corporation | $40.79 | 2019-2022 | |
| Gilead Sciences, INC. | $40.78 | 2021-2023 | |
| Verastem, INC. | $40.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.04 | 2020-2023 | Alunbrig |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $38.01 | 2023 | Libtayo |
| Foundation Medicine, INC. | $37.77 | 2019 | |
| Kite Pharma, INC. | $36.01 | 2021 | |
| Amag Pharmaceuticals, INC. | $31.10 | 2019-2021 | |
| Puma Biotechnology, INC. | $30.70 | 2020-2022 | |
| Taiho Oncology, INC. | $30.31 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.43 | 2019-2020 | |
| Genzyme Corporation | $23.73 | 2021 | |
| Abbvie INC. | $23.41 | 2024 | |
| Eisai INC. | $20.03 | 2021 | |
| Genentech USA, INC. | $19.60 | 2019 | |
| Array Biopharma INC | $15.21 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.74 | 2019 | |
| Emmaus Medical, INC. | $6.84 | 2023 | Endari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Coplin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.